GMED

Quest Diagnostics Incorporated DGX reported third-quarter 2026 adjusted earnings of $3.00 per share, up 15.4% year over year. The figure beat the Zacks Consensus Estimate by 5.3%. GAAP earnings were $2.78 per share, up 28.7% from the prior-year figure. Revenues rose 10% year over year to $3.10 billion, surpassing the Zacks Consensus Estimate by 1.7%. Growth was supported by strong testing demand across physician, hospital and consumer channels, with organic requisition volume increasing 14.4%. DGX's shares have lost nearly 1.6% in pre-market trading following the earnings report. Diagnostic Information Services revenues increased 10.2% year over year to $3.04 billion. The business accounted for nearly all consolidated revenues, reflecting continued strength across the company's core testing channels. Total requisition volume increased 14.5% year over year, while organic requisition volume climbed 14.4%. However, revenue per requisition declined 4.2%, partially offsetting the benefits of higher testing volumes. Despite the lower revenue per requisition, robust testing demand helped sustain double-digit revenue growth. The cost of services during the reported quarter was $2.06 billion, up 10.1% year over year. Gross profit increased 9.8% to $1.04 billion from $949 million in the year-ago quarter. The gross margin remained relatively stable at approximately 33.6%. Selling, general and administrative expenses totaled $523 million, increasing 4.4% year over year. Reported operating income surged 24.2% to $479 million, while the operating margin expanded 180 basis points to 15.5%. Adjusted operating income increased 13% to $517 million. The adjusted operating margin improved 40 basis points to 16.7%, reflecting stronger operating profitability. Quest Diagnostics exited the third quarter with cash and cash equivalents of $797 million compared with $626 million at the end of the second quarter. The company generated $611 million in operating cash flow during the quarter, up 8.8% from $563 million a year ago. For the first nine months of 2026, operating cash flow increased 4.6% to $1.49 billion. Capital expenditures totaled $418 million, up 13.3% year over year. During the same period, the company spent $252 million on share repurchases and paid $279 million in dividends. Quest Diagnostics raised its full-year 2026 revenue guidance to $12.065-$12.105 billion from the previous projection of $11.95-$12.05 billion. The updated outlook represents expected revenue growth of 9.3-9.7%. The Zacks Consensus Estimate is pegged at $12.01 billion, indicating an increase of 8.9% from the year-ago figure. The company increased its adjusted earnings guidance to $11.25-$11.35 per share from $11.05-$11.25. The Zacks Consensus Estimate for the metric is pegged at $11.15. Quest Diagnostics expanded its Alzheimer's disease testing portfolio by adding Roche's FDA-cleared Elecsys Phospho-Tau (217P) Plasma blood test to its AD-Detect menu. It also launched a new panel combining pTau217, amyloid beta and APOE biomarkers to support diagnosis and treatment decisions. On the partnership front, Quest finalized an agreement to acquire select outreach laboratory assets from a Northeastern U.S. health system. It also advanced its Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan. Quest Diagnostics Incorporated price-consensus-eps-surprise-chart | Quest Diagnostics Incorporated Quote Quest Diagnostics ended the third quarter of 2026 with earnings and revenues surpassing their respective estimates. Revenue growth was driven by sustained demand for diagnostic testing services, supported by contributions from the company's expanding laboratory operations. Productivity improvements from automation and artificial intelligence also supported the company's performance. Driven by the robust third-quarter performance, Quest Diagnostics raised its full-year 2026 guidance. Additionally, the improvement in operating margin during the quarter is a positive development. Quest Diagnostics currently has a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Phibro Animal Health PAHC, Agilent Technologies A and Globus Medical GMED . Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy), reported fourth-quarter fiscal 2026 adjusted EPS of 85 cents, which surpassed the Zacks Consensus Estimate by 18.06%. Revenues of $396.7 million beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today's Zacks #1 Rank stocks here. PAHC has an earnings yield of 8.9% compared with the industry's 2.8%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 18.36%. Agilent Technologies,carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2026 adjusted EPS of $1.62, exceeding the Zacks Consensus Estimate by 9.5%. Revenues of $1.88 billion topped the Zacks Consensus Estimate by 2.1%. A has an earnings yield of 3.7% compared with the industry's 2.8%. The company's earnings outpaced estimates in two of the trailing four quarters, broke even once and missed on another one, the average surprise being 3.8%. Globus Medical,carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.34, exceeding the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million outperformed the Zacks Consensus Estimate by 0.4%. GMED has an estimated earnings yield of 6.6% against the industry's 2.3% decline. The company's earnings outpaced estimates in each of the trailing four quarters, the average surprise being 27.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Abbott ABT reported third-quarter 2026 adjusted earnings per share of $1.42, up 9.2% year over year. The figure missed the Zacks Consensus Estimate by 0.7%. Sales increased 14.5% year over year to $13.01 billion, surpassing the consensus mark by 0.3%. Comparable sales rose 7%, supported by growth across all four operating segments. Following the earnings announcement, ABT stock fell 3.6% in pre-market trading today. Medical Devices sales increased 6.9% year over year on a reported basis to $5.83 billion. Comparable sales advanced 7.8%, reflecting growth across several cardiovascular and diabetes-care businesses. Electrophysiology sales climbed 15.5% on a comparable basis, while Rhythm Management and Heart Failure advanced 10% and 6%, respectively. Diabetes Care sales grew 6.7%, supported by a 7.7% increase in continuous glucose monitor (CGM) sales. Vascular sales improved 5.7%, while Structural Heart rose 6.9%. Neuromodulation sales declined 1.1%. Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Diagnostics sales surged 46.7% year over year on a reported basis to $3.31 billion, reflecting contributions from the March 2026 acquisition of Exact Sciences. Comparable sales increased 6.4%. Cancer Diagnostics sales totaled $968 million and grew 13.8% on a comparable basis. Performance benefited from Cologuard growth and contributions from precision oncology and international operations. Core Laboratory Diagnostics sales increased 5.4%, driven by balanced growth across the United States, Europe, Japan and Latin America. Rapid and Molecular Diagnostics sales improved 0.9% on a comparable basis, supported by modest growth in both domestic and international markets. Nutrition sales increased 5.1% year over year on a reported basis to $2.26 billion. Comparable sales rose 4.9%, reflecting broad-based improvement across the portfolio. Pediatric Nutrition sales advanced 8.7% on a comparable basis, while Adult Nutrition increased 1.8%. U.S. Nutrition sales climbed 7.9%, supported by 11% growth in domestic Pediatric Nutrition. International Nutrition sales rose 2.8% on a comparable basis. Total Nutrition revenues also improved sequentially by $118 million from the second quarter of 2026. Established Pharmaceuticals sales increased 6.8% year over year on a reported basis to $1.61 billion. Comparable sales grew 8.4%, reflecting continued expansion across international markets. Key Emerging Markets sales advanced 10.9% on a comparable basis, supported by double-digit growth in India and several Latin American and Asia-Pacific markets. Sales in other markets increased 1.6% on a comparable basis. Key Emerging Markets generated $1.20 billion in quarterly revenues, while other markets contributed $419 million. In the third quarter, adjusted gross profit increased 17.4% year over year to $7.45 billion. The adjusted gross margin expanded approximately 143 basis points (bps) to 57.2%. Adjusted selling, general and administrative expenses increased 16.7% year over year to $3.51 billion. Adjusted research and development expenses grew 22.2% to $892 million. Adjusted operating profit rose 16.9% to $3.05 billion, while the adjusted operating margin expanded approximately 49 bps to 23.4%. Abbott tightened its full-year 2026 adjusted earnings guidance to $5.50-$5.55 per share, reaffirming the midpoint of its previous $5.45-$5.60 range. The Zacks Consensus Estimate currently stands at $5.53 per share. The company now projects approximately 6% comparable sales growth for 2026 compared with its previous guidance of 6.5%-7.5%. For the fourth quarter, management expects adjusted EPS of $1.62-$1.67. The Zacks Consensus Estimate for the same stands at $1.65. Abbott exited the third quarter of 2026 with an earnings miss, while revenues surpassed expectations. Within Diagnostics, Core Laboratory results benefited from balanced growth across the United States, Europe, Japan and Latin America. Cancer Diagnostics gained from Cologuard growth and contributions from precision oncology and international operations. Strong performance in Electrophysiology and Rhythm Management supported Medical Devices results. The expansion of the adjusted gross margin and recovery in Nutrition sales are also encouraging. Meanwhile, higher operating expenses and a reduction in the full-year comparable sales growth outlook remain concerns. Abbott also highlighted several product developments. The company secured FDA approval for Libre Duo, a dual glucose-ketone wearable sensor, and TactiFlex Duo, an ablation catheter for treating atrial fibrillation. It also received CE Mark approval for Amulet 360, launched the SimpleScreen CRC blood-based colorectal cancer screening test and introduced Similac 360 Total Care Made With Whole Milk in the United States. Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Phibro Animal Health PAHC, Agilent Technologies A and Globus Medical GMED. Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy), reported fourth-quarter fiscal 2026 adjusted EPS of 85 cents, which surpassed the Zacks Consensus Estimate by 18.06%. Revenues of $396.7 million beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PAHC has an earnings yield of 8.9% compared with the industry's 2.8%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 18.36%. Agilent Technologies,carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2026 adjusted EPS of $1.62, exceeding the Zacks Consensus Estimate by 9.5%. Revenues of $1.88 billion topped the Zacks Consensus Estimate by 2.1%. A has an earnings yield of 3.7% compared with the industry's 2.8%. The company's earnings outpaced estimates in two of the trailing four quarters, broke even once and missed on another one, the average surprise being 3.8%. Globus Medical,carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.34, exceeding the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million outperformed the Zacks Consensus Estimate by 0.4%. GMED has an estimated earnings yield of 6.6% against the industry's 2.3% decline. The company's earnings outpaced estimates in each of the trailing four quarters, the average surprise being 27.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Intuitive Surgical, Inc. ISRG reported third-quarter 2026 adjusted earnings per share (EPS) of $3.00, which beat estimates by 13.6%. The bottom line increased 25% from $2.40 in the year-ago quarter. GAAP EPS declined to $1.49 from $1.95, reflecting a significant litigation charge. Revenues increased 21.7% year over year to $3.05 billion, surpassing expectations by approximately 4.9%. Growth was driven by higher procedure volumes, increased system placements and an expanding installed base. Worldwide da Vinci and Ion procedures collectively grew approximately 15%. Image Source: Zacks Investment Research Instruments and accessories revenues increased 18.3% year over year to $1.80 billion from $1.52 billion. This growth reflected a 14% increase in da Vinci procedures and 31% growth in Ion procedures. U.S. da Vinci procedures increased 10%, while international procedures advanced 20%. Europe grew 20%, Asia increased 19% and Rest of World markets expanded 22%. India recorded 42% procedure growth, while Japan benefited from improving reimbursement conditions. Single-port procedures climbed 55%, supported by expanding adoption in the United States and Korea. Da Vinci instruments and accessories revenue per procedure increased to approximately $1,860 from $1,800, benefiting from favorable product mix and greater adoption of newer instruments. Systems revenues jumped 30.3% year over year to $769.1 million from $590.4 million, reflecting stronger placements and higher operating lease revenues. Intuitive placed 546 da Vinci systems compared with 427 a year earlier. Placements included 315 da Vinci 5 systems, 87 Xi, 65 XiR, 42 SP and 37 X systems. The company also placed 56 Ion systems versus 50 last year. U.S. placements increased 27% to 335 systems, while international placements rose 29% to 211. Europe recorded 115 placements, up from 63 a year ago. The worldwide da Vinci installed base expanded 12% to 12,094 systems, while Ion's installed base increased 21% to 1,152. Service revenues increased 21.8% year over year to $482.2 million from $395.9 million. Growth reflected expansion of the da Vinci and Ion installed bases and a higher proportion of da Vinci 5 systems. Recurring revenues represented approximately 84% of total quarterly revenues, underscoring the contribution of instruments, accessories, leasing and services to Intuitive's business model. Adjusted gross profit increased 25% to $2.13 billion from $1.70 billion. The adjusted gross margin expanded to 69.9% from 68% a year earlier, benefiting from product cost reductions, manufacturing efficiencies and tariff refunds. The quarter included a $28 million pretax tariff refund benefit. Excluding this item, adjusted gross margin was 68.9%, representing a 90-basis-point year-over-year improvement. Adjusted operating income rose 30.1% to $1.27 billion. Adjusted operating expenses increased 18%, reflecting higher compensation, headcount and prototype development spending. Intuitive ended September with $6.80 billion in cash, cash equivalents and investments, down $1.83 billion sequentially. The decline primarily reflected significant shareholder returns and capital investments. The company repurchased 7.8 million shares for $2.94 billion during the quarter. Capital expenditures totaled $113 million. GAAP net income declined to $523 million from $704 million, including a $450 million pretax charge related to an antitrust litigation settlement. Intuitive narrowed its full-year worldwide da Vinci procedure growth forecast to 14-15% from the previous 13.5-15.5% guidance. Management expects growth closer to the midpoint. The company raised its adjusted gross margin outlook to 68.7-69.3% from 68-69%, incorporating an estimated 90-basis-point tariff impact. Adjusted operating expense growth guidance remains at 11-13%. Management also outlined instrument pricing reductions beginning in 2027 and policy-driven reductions in China starting in November 2026. Together, these measures are expected to reduce da Vinci instruments and accessories revenue per procedure by 3-5% on a constant-mix basis, once fully implemented. The pricing initiatives target high-volume benign procedures where affordability limits robotic surgery adoption. Although they could pressure revenue per procedure, management expects lower customer costs, expanded access and continued innovation to support procedure growth over time. Intuitive Surgical, Inc. price-consensus-eps-surprise-chart | Intuitive Surgical, Inc. Quote Intuitive Surgical currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Glaukos GKOS, Edward Lifesciences EW and Globus Medical GMED, each carrying a Zacks Rank of 2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%. Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS' earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%. Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%. Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%. Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%. Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Globus Medical has delivered a mixed share price story, with a strong multi year return sitting alongside shorter term pullbacks. This raises a simple question for you as an investor: Is the current price of US$76.31 adequately backed by the earnings this spinal and orthopedic specialist produces today and is expected to generate in the years ahead? - Over the past 3 years the stock has returned 41.6%, which puts real weight on whether current earnings can carry that kind of value creation further. - The business model relies heavily on translating surgical volume and product mix into consistent earnings, so any shift in hospital spending or procedure trends can influence how comfortably those earnings support the present share price. - The analysts covering Globus Medical have run their own numbers. See what analysts think Globus Medical's shares could be worth. The issue now is whether Globus Medical's current valuation is properly supported by its earnings power when judged against the Fair Ratio benchmark. If you want to explore the same earnings-based valuation question beyond Globus Medical, you can compare it to 32 high quality undervalued stocks. The P/E ratio suits Globus Medical because profitability sits at the center of how investors usually judge mature medical equipment businesses. On this metric, the stock trades on roughly 19.1x earnings, which comes in below the broader medical equipment sector average of about 24.5x and well under the peer group near 37.8x. That gap tells you the market is not assigning the same earnings premium to Globus Medical that it gives to many listed rivals. A Fair Ratio model that folds in Globus Medical's size, industry, margins and risk profile points to a higher P/E than the one currently on the screen. As a result, the shares change hands at a discount to what that tailored yardstick might imply is appropriate, even before you factor in where many peers trade. For an investor weighing how much is already priced into the earnings stream, the current multiple leaves room for debate rather than a fully stretched story. Explore the numbers behind Globus Medical's P/E valuation. Narratives for Globus Medical pick up where the P/E puzzle leaves off by spelling out which future paths for growth, profitability and earnings would need to play out for the current valuation to look either conservative or demanding. Each scenario links its numbers to a clear view on how Globus Medical's growth, margins and risk profile might evolve, giving you something concrete to revisit as fresh information comes through. One of the top community narratives on Globus Medical: 24% undervalued "The main thing that has to go right is continued execution on margin expansion from manufacturing efficiencies and M&A synergies..." Discover why this Narrative puts Globus Medical at 24% undervalued. Earnings multiples only tell you what the market pays for Globus Medical today, while analyst projections sketch where the business could be a few years from now and set a different reference point for you to test. Explore where analysts expect Globus Medical to be in a few years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GMED. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Becton, Dickinson and Company BDX, popularly known as BD, recently reported positive nine-month results from the iliac cohort of the AGILITY trial evaluating its Revello Vascular Covered Stent for treating iliac artery disease, a form of peripheral artery disease (PAD). The findings, presented at VIVA 2026, showed promising safety and effectiveness and support continued clinical evaluation of the device. The results are encouraging for BD as it seeks to strengthen its position in the peripheral vascular market through product innovation and clinical evidence. If subsequent follow-up confirms the device's durability and effectiveness, Revello could expand BD's growth opportunities in vascular intervention. Although Revello is CE-marked, it remains under clinical development in the United States and is limited to investigational use under U.S. law. Its commercial potential will depend on further clinical results and regulatory progress. Following the announcement on Oct. 7, BDX stock has gained more than 2% till yesterday's close. Year to date, shares of the company have lost 2.7% against the industry's 9.5% growth and the S&P 500's 12.5% rise. The positive AGILITY trial results could support BDX's long-term growth by strengthening its portfolio of peripheral vascular intervention products and expanding clinical evidence for the Revello Vascular Covered Stent. Favorable outcomes may improve physician confidence in the device and support its adoption if it secures the necessary regulatory approvals. This could create an additional growth opportunity for BD in treating peripheral artery disease while complementing its broader vascular portfolio. However, long-term revenue contribution will depend on the completion of clinical follow-up, regulatory clearance in the United States and the device's eventual commercial uptake. BDX currently has a market capitalization of $51.63 billion. Image Source: Zacks Investment Research BD's AGILITY Investigational Device Exemption trial evaluated the Revello Vascular Covered Stent in patients with iliac artery disease, which can restrict blood flow to the legs and feet, causing pain, cramping and reduced mobility. The iliac cohort enrolled 120 patients across 28 investigational sites in the United States, Europe, Australia and New Zealand. At nine months, the study met its primary composite safety and effectiveness endpoint, with a failure rate of just 2.8%, well below the prespecified performance goal of 19%. The results also showed 97.2% primary patency, indicating that the treated arteries remained open. Trial data also demonstrated 98.3% freedom from clinically driven target lesion revascularization, suggesting a low need for repeat procedures due to clinical symptoms. Additionally, there were no device- or procedure-related deaths, no major amputations in the target limb at or above the ankle, or unanticipated serious adverse device effects. These findings support the stent's performance in treating iliac artery disease, including cases involving moderate-to-severe lesion calcification. The Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with radial resistive force tailored to the iliac arteries. Beyond safety and vessel patency, patients treated in the AGILITY trial showed improvements in disease severity and walking ability. The mean Rutherford category, a measure of peripheral artery disease severity, improved from 3.0 at baseline to 0.3 at nine months, while the mean Walking Impairment Questionnaire score increased by 31.7 points. Women accounted for approximately 41% of enrolled patients, adding to the diversity of the study population. Clinical follow-up in the iliac cohort will continue through 36 months to assess the durability of the results. BD also completed enrollment in the trial's superficial femoral and proximal popliteal artery cohort in August 2026, extending the study's evaluation of the device across additional peripheral vascular applications. Continued positive results and progress toward regulatory approval could strengthen BD's competitive position in peripheral intervention, although broader commercial adoption will depend on longer-term clinical outcomes and regulatory developments. Going by data provided by Grand View Research, the global iliac stent market size was valued at $1.2 billion in 2025 and is projected to grow from $1.3 billion in 2026 to $2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Growth of the market can be attributed to growing advancements in medical technology, increasing prevalence of peripheral artery diseases and expanding awareness about minimally invasive procedures as an effective treatment option. BD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access. Currently, BDX carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI. OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today's Zacks #1 Rank stocks here. OPK has an estimated earnings growth rate of 23.3% for 2026. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%. Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. GMED has an estimated long-term earnings growth rate of 12.4%. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%. MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI's earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after the market close on Thursday, November 5, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcasts. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investors page of the Globus Medical website. About Globus Medical, Inc. Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"), including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the "Company", "Globus", "Globus Medical", "we", "us", and "our" refers to Globus Medical, Inc. Contact Shagun Singh Senior Vice President, Strategy and Investor Relations (610) 930-1800 [email protected]

AngioDynamics, Inc. ANGO reported an adjusted loss per share of 4 cents for first-quarter fiscal 2027, narrower than the year-ago quarter's adjusted loss of 10 cents. The figure also beat the consensus estimate by 60%. Revenues totaled $80.9 million, up 6.9% year over year, in line with the Zacks Consensus Estimate. Growth was primarily driven by strong Med Tech performance, particularly Auryon, AlphaVac and NanoKnife. The company also recorded a substantial improvement in gross margin. AngioDynamics continued to benefit from its strategic shift toward higher-growth Med Tech products. The business contributed approximately 49% of total revenues compared with 47% in the year-ago period. Management expects Med Tech to account for a majority of total revenues during fiscal 2027. The company recorded its eighth consecutive quarter of double-digit Med Tech revenue growth and positive adjusted EBITDA. However, shares of this company lost more than 20% during yesterday's trading. In the quarter under review, U.S. net revenues totaled $71.1 million, reflecting an improvement of 6.9% from the year-ago quarter's $66.5 million. International revenues amounted to $9.8 million, up 6.4% from the prior-year period's $9.3 million. Growing international adoption of the Auryon platform, following its CE Mark approval, supported the company's expansion efforts. AngioDynamics derives revenues from two businesses — Med Tech and Med Device. Med Tech Med Tech revenues totaled $39.9 million, increasing 13.2% from the prior-year quarter. Auryon sales reached $18.9 million, reflecting 14.7% growth and marking the platform's 21st consecutive quarter of double-digit year-over-year growth. Increasing adoption across hospitals and office-based laboratories supported performance. Mechanical Thrombectomy revenues increased 6.7% to $12 million. AlphaVac revenues climbed 37.4% to $4.5 million, while AngioVac revenues declined 5.9% to $7.5 million. Sequentially, AlphaVac and AngioVac revenues grew 6.4% and 9.1%, respectively. NanoKnife revenues jumped 29% to $8.3 million, supported by 24.1% growth in probe sales and 53.5% growth in capital sales. Management highlighted record prostate procedure volumes, reflecting increasing physician adoption. Med Device Med Device revenues reached $41 million, up 1.4% from $40.4 million in the comparable period. Management continues to view this business as a consistent source of cash generation and profitability, supporting investments in higher-growth Med Tech platforms. AngioDynamics, Inc. price-consensus-eps-surprise-chart | AngioDynamics, Inc. Quote Gross profit increased 14.8% year over year to $48 million. Gross margin expanded 410 basis points to 59.4%, primarily benefiting from favorable pricing and a greater contribution from higher-margin Med Tech products. Excluding tariff refunds, gross margin was 57.8%. Research and development expenses increased 24.3% year over year to $8 million. Sales and marketing expenses rose 6.6% year over year to $30 million, while general and administrative expenses declined 0.7% to $12.5 million. Total operating expenses increased 5.4% year over year to $55.3 million. However, operating loss narrowed year over year to $7.3 million from $10.7 million. AngioDynamics exited the first quarter of fiscal 2027 with cash of $33.9 million compared with $53.9 million at the fiscal 2026 end. The company ended the quarter with no debt on its balance sheet. Net cash used in operating activities totaled $15.3 million compared with $15.9 million in the prior-year quarter. Management expects positive operating cash flow for the full fiscal year, with the fiscal fourth quarter likely to generate the strongest cash inflows. AngioDynamics reiterated its fiscal 2027 revenue guidance of $336-$341 million, representing projected growth of 5-6.5% year over year. The Zacks Consensus Estimate is currently pegged at $338.5 million. Med Tech revenue growth is expected between 12% and 15%, while Med Device revenues are projected to remain flat. Management continues to expect gross margin of 54-55% and adjusted EBITDA between $13 million and $16 million. Adjusted loss per share is anticipated between 29 cents and 24 cents. The company expects tariff-related impacts to remain broadly comparable to fiscal 2026, excluding refunds. The adjusted loss per share is projected to be between 29 cents and 24 cents. The Zacks Consensus Estimate is currently pegged at a loss of 26 cents per share. AngioDynamics, Inc. price | AngioDynamics, Inc. Quote AngioDynamics' expanding clinical portfolio strengthens its long-term Med Tech growth opportunities. The FDA's Investigational Device Exemption approval for the RELIEF study represents a notable development for NanoKnife. The study will evaluate the technology for treating benign prostatic hyperplasia, potentially expanding its applications beyond oncology. NanoKnife reimbursement progress, including a favorable Medicare Administrative Contractor coverage decision, could support wider adoption. Meanwhile, ongoing AlphaReturn and AngioVac clinical studies, alongside Auryon's AMBITION BTK study, offer additional opportunities for expanding the company's addressable markets. The company also announced that Eric Honroth will succeed Jim Clemmer as president and CEO, effective Nov. 2, 2026. Honroth's extensive medical technology leadership experience could support the company's next phase of growth as it continues executing the Med Tech-focused strategy. ANGO currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today's Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. VCYT has an estimated earnings growth rate of 8.4% for 2026. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%. West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. West Pharmaceutical's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the medical devices & supplies - specialty industry, including Globus Medical (NYSE:GMED) and its peers. The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers. The 7 medical devices & supplies - specialty stocks we track reported a very strong Q2. As a group, revenues beat analysts' consensus estimates by 2.1%. In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results. With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures. Globus Medical reported revenues of $789.6 million, up 5.9% year on year. This print exceeded analysts' expectations by 0.9%. Overall, it was a very strong quarter for the company with an impressive beat of analysts' full-year EPS guidance estimates and a beat of analysts' EPS estimates. "Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of our underlying businesses, most notably US Spine, growing 7% and International Spine, growing 14% as-reported and 12% on a constant currency basis," commented Keith Pfeil, President and Chief Executive Officer. Investor expectations, however, were likely higher than Wall Street's published projections, leaving some wishing for even better results (analysts' consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 8.8% since reporting and currently trades at $73.94. Is now the time to buy Globus Medical? Access our full analysis of the earnings results here, it's free. Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep. Inspire Medical Systems reported revenues of $200.6 million, down 7.6% year on year, outperforming analysts' expectations by 3%. The business had an exceptional quarter with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. Inspire Medical Systems achieved the highest full-year guidance raise of the whole group. The market seems happy with the results as the stock is up 32.3% since reporting. It currently trades at $69.08. Is now the time to buy Inspire Medical Systems? Access our full analysis of the earnings results here, it's free. With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation. Enovis reported revenues of $582.8 million, up 3.2% year on year, in line with analysts' expectations. It was a mixed quarter as it posted a beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Enovis delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 39.6% since the results and currently trades at $18.24. Read our full analysis of Enovis's results here. With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens. STAAR Surgical reported revenues of $93.54 million, up 111% year on year. This result topped analysts' expectations by 3.3%. Overall, it was a very strong quarter as it also produced a beat of analysts' EPS estimates. STAAR Surgical delivered the biggest analyst estimate beat and fastest revenue growth among its peers. The stock is down 21.8% since reporting and currently trades at $19.87. Read our full, actionable report on STAAR Surgical here, it's free. With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE:HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals. Haemonetics reported revenues of $339.4 million, up 5.6% year on year. This number beat analysts' expectations by 2.8%. Overall, it was a very strong quarter as it also put up a solid beat of analysts' organic revenue estimates and a beat of analysts' EPS estimates. The stock is up 27.8% since reporting and currently trades at $106.86. Read our full, actionable report on Haemonetics here, it's free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market's biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market's primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market's dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Globus Medical has delivered a 45.9% gain over the past three years, even after a weaker recent patch, which puts a spotlight on one simple question. Is the current share price of US$74.08 adequately backed by the orthopedics specialist's earnings power. The 45.9% return over three years leaves existing holders sitting on material gains. The issue now is whether those profits reflect sustainable earnings or just a richer multiple. The business leans on selling spinal implants and related hardware. Long term earnings support will depend heavily on how efficiently it converts procedure volume into margins and cash flow. The analysts covering Globus Medical have run their own numbers. See what analysts think Globus Medical's shares could be worth. The stock's next move may depend on whether Globus Medical's current earnings are strong enough to justify today’s valuation or whether expectations have run ahead of the underlying business. If you are weighing Globus Medical against other ideas and want a broader watchlist of companies with similar potential, a focused stock screen built around solid balance sheet and fundamentals stocks screener (23 results). The P/E ratio is a useful way to think about Globus Medical because earnings remain the main anchor for how this kind of medical equipment business is valued. At the current share price, the stock trades on a P/E of about 18.6x, which is below both the broader medical equipment industry average of roughly 24.8x and a peer group closer to 37.8x. That discount is larger than the tailored benchmark suggested by the fair-value model, which points to a higher P/E as consistent with Globus Medical’s mix of growth prospects, profitability profile and risk. For an investor, the gap signals that the market is pricing the shares more cautiously than that framework would imply, and that the current earnings yield could be attractive if the business continues to justify its standing in spinal hardware and related products. Explore the numbers behind Globus Medical's P/E valuation. Globus Medical’s Narratives pick up where the valuation puzzle leaves off. They spell out which future paths for growth, margins and earnings would line up with a higher or lower share price than today. They also turn a single ratio or model output into a set of concrete assumptions you can watch over time to see whether that valuation case still holds on Simply Wall St’s Community page. One of the top community narratives on Globus Medical: 28% undervalued Discover why this Narrative puts Globus Medical at 28% undervalued. Before you file Globus Medical away as cheap, expensive, or somewhere in between, it helps to see where professional forecasts expect its earnings power to sit a few years from now and how that lines up with today’s multiples. Explore where analysts expect Globus Medical to be in a few years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GMED. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

The Cooper Companies, Inc. COO reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.15, up 4.5% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%, aided by expense management and productivity initiatives. GAAP EPS for the quarter was $2.24, significantly up from the year-ago period’s figure of 49 cents, primarily driven by a $307.2 million discrete tax benefit following the favorable completion of a U.K. tax examination. COO’s fiscal third-quarter revenues rose 0.6% year over year to $1.066 billion but missed the Zacks Consensus Estimate of $1.099 billion by 3.0%. The quarterly revenues were up 1% year over year at the constant exchange rate (CER). U.S. CooperVision channel inventory reductions weighed on sales. MiSight remained a bright spot, delivering 20% organic growth. Shares of COO were down 15.9% in after-hours trading following the earnings call. The company’s shares have lost 22.5% in the year-to-date period against the industry’s 4.6% growth. However, the S&P 500 Index was up 11% during the same period. Image Source: Zacks Investment Research For the third quarter of fiscal 2026, CooperVision (CVI) revenues were $717.0 million, flat year over year on a reported, CER and organic basis. The segment faced pressure from proactive U.S. channel inventory reductions, which offset underlying demand and strength in several premium product categories. Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others. Toric and multifocal revenues were $363.8 million, up 1% year over year and 2% at CER as well as organically. Sphere and other revenues totaled $353.2 million, declined 2% year over year on a reported basis and fell 1% at CER as well as organically. MyDay toric, MyDay multifocal and MyDay Energys each recorded double-digit growth, while MiSight maintained strong momentum. In the third quarter of fiscal 2026, CooperSurgical (CSI) revenues were $349.2 million, up 2% year over year on a reported basis as well as at CER and grew 3% organically. Category-wise, CSI derives revenues from Office and Surgical, and Fertility. Office and Surgical revenues were $208 million, up 2% on a reported and organic basis as well as at CER. Medical Devices grew 4%, driven by strength in surgical OB/GYN and specialty device portfolios, while Paragard revenues were flat. Management continued to point to genomics and adoption of the Witness automated laboratory management platform as contributors to fertility performance. Fertility revenues were $141.2 million, up 3% year over year on a reported basis, up 4% at CER with organic growth of 5%, supported by broad-based strength across products and services, new clinic wins and expansion within existing accounts. Geographically, growth was led by the Americas, while EMEA and Asia Pac remain mixed as strength across several markets was offset by macro headwinds in the Middle East and China. Within CVI, Americas revenues totaled $281.6 million, down 2% year over year on a reported basis, at CER and organically. The weakness reflected the company's decision to reduce U.S. channel inventory. Management noted that Americas revenues would have grown around 5% without the inventory actions, while underlying U.S. consumption remained at a mid-single-digit growth rate. EMEA revenues were $309.4 million, up 6% year over year on a reported basis and 5% at CER as well as organically, supported by continued strength across premium offerings. Asia Pacific revenues totaled $126 million, down 10% on a reported basis and 5% at CER and organically, with portfolio rationalization and softer conditions in certain markets weighing on performance. In the quarter under review, Cooper Companies’ adjusted gross profit declined 0.3% year over year to $711.1 million. The adjusted gross margin was 66.7%, down 60 basis points (bps) from the year-ago period, reflecting higher manufacturing costs and unfavorable foreign exchange. Selling, general and administrative expenses decreased 4.8% to $401.3 million. Research and development expenses fell 6.7% to $41.6 million. Adjusted operating costs totaled $430.4 million, reflecting a 1.5% decrease from the prior-year quarter’s level. Adjusted operating profit totaled $280.7 million, up 1.6% from the year-earlier quarter’s level. The adjusted operating margin expanded 30 bps to 26.3%, aided by productivity improvements and disciplined expense management. COO exited the third quarter of fiscal 2026 with cash and cash equivalents of $154.7 million compared with $138.8 million at the end of the second quarter of fiscal 2026. Total debt at the end of the fiscal third quarter was $2.54 billion compared with $2.46 billion at the end of the fiscal second quarter. Cooper Companies has issued its outlook for the fiscal fourth quarter and updated its guidance for fiscal 2026. For the fourth quarter of fiscal 2026, Cooper Companies expects revenues of $1.057-$1.080 billion, representing organic growth of 0-2%, and adjusted EPS of $1.05-$1.09. CVI revenues are projected at $692-$706 million, implying organic growth of negative 2% to flat, as U.S. inventory reductions continue. CSI revenues are expected at $364-$374 million, representing organic growth of 4-6%. For fiscal 2026, revenues are now forecast at $4.229-$4.252 billion, with adjusted EPS of $4.51-$4.55. The company expects CVI revenues of $2.828-$2.842 billion, representing organic growth of 1-2% and CSI revenues of $1.401-$1.410 billion, representing organic growth of 4-5%, while reaffirming its objective of more than $2.2 billion in cumulative free cash flow for fiscal 2026-2028. The Cooper Companies, Inc. price-consensus-eps-surprise-chart | The Cooper Companies, Inc. Quote Cooper Companies delivered a mixed third-quarter fiscal 2026 performance, with earnings topping expectations despite softer revenues. CooperVision’s results were hurt by proactive U.S. channel inventory reductions, although underlying consumption in the United States remained healthy at a mid-single-digit growth rate. Strength in premium products continued, with MyDay toric, multifocal and Energys posting double-digit growth, while MiSight delivered 20% organic growth. CooperSurgical remained resilient, led by growth in fertility, supported by genomics, new clinic wins and broader adoption of the Witness platform. CooperVision’s near-term growth is likely to remain pressured as management expects a similar level of U.S. channel inventory reduction in the fiscal fourth quarter. However, the company expects the majority of the destocking and legacy hydrogel portfolio rationalization to be completed by fiscal year-end, positioning the business for a healthier start to fiscal 2027. COO is also stepping up commercial investments through expanded sales coverage, marketing programs and AI-driven targeting tools. New product initiatives, including MyDay MiSight and upcoming toric and multifocal offerings, should support longer-term growth. CooperSurgical remains another key growth driver, particularly in fertility, where favorable treatment trends, growing access to IVF and strength in genomics support the outlook. Following its strategic review, the board decided to retain CooperSurgical after determining that transaction proposals did not adequately reflect the business’ long-term value. Foreign exchange headwinds, higher manufacturing costs and increased commercial investments are expected to pressure margins in the fourth quarter, while continued weakness in Asia Pacific and CooperVision destocking remain near-term concerns. COO currently has a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and West Pharmaceutical WST. Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here. VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%. Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%. West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

The Cooper Companies COO is scheduled to report third-quarter fiscal 2026 results on Sept. 9, after market close. The Zacks Consensus Estimate for sales is pegged at $1.1 billion, implying 3.6% year-over-year growth. The consensus estimate for the bottom line is pinned at $1.11 per share, suggesting growth of 0.9%. The earnings per share (EPS) estimates have remained stable over the past seven days. The company delivered an earnings surprise of 10% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.8%. What the Zacks Model Unveils for COO Our proven model does not conclusively predict an earnings beat for The Cooper Companies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. COO’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank of COO: The company carries a Zacks Rank #4 (Sell) at present. The Cooper Companies, Inc. price-eps-surprise | The Cooper Companies, Inc. Quote The Cooper Companies’ fiscal third-quarter performance is expected to have benefited from continued strength in its CooperVision business, improving fertility trends within CooperSurgical and ongoing operational efficiency initiatives. Management maintained its fiscal 2026 adjusted EPS guidance of $4.58-$4.66 after a strong fiscal second quarter, reflecting confidence in execution despite macroeconomic headwinds in Asia Pacific. CooperVision is likely to have remained the company's primary growth driver during the to-be-reported quarter. Revenue growth is expected to have been supported by healthy demand in the Americas and EMEA, where premium daily silicone hydrogel lenses, particularly the MyDay portfolio, continued gaining traction through expanding customer partnerships and branded contract wins. Biofinity toric and multifocal lenses are also expected to have contributed meaningfully, while MyDay multifocal and Energys likely sustained strong adoption, supported by their premium positioning and broader rollout across markets. Myopia control products are expected to have remained a meaningful growth contributor. MiSight delivered 24% growth in the prior quarter, driven by strong momentum in Japan, encouraging adoption of MyDay MiSight in Europe and expanding consumer awareness campaigns during the back-to-school season. Management indicated that clinician reception remained favorable and investments in additional product launches should continue supporting long-term growth, even as increasing adoption of spectacle-based myopia control products creates some near-term competitive pressure. Within CooperSurgical, fertility trends are expected to have remained favorable as IVF market conditions continued improving across key markets. Management expects the fertility business to return to mid-single-digit growth during the second half after a stronger-than-expected prior quarter that benefited from capital equipment sales and temporary distributor restocking in the Middle East. Continued demand for genomics, consumables and Witness laboratory tracking systems, along with new clinic wins and expansion within existing accounts, is expected to have supported quarterly performance. Regionally, the Americas and EMEA are expected to have maintained healthy growth trajectories, but Asia Pacific is likely to have remained a meaningful headwind. Management had guided for another quarterly decline in the region due to persistent consumer weakness in Japan and China, continued rationalization of legacy hydrogel products and rising e-commerce activity, where The Cooper Companies has relatively lower exposure. On the profitability front, restructuring benefits, disciplined cost management and technology-driven efficiency initiatives are expected to have continued supporting operating leverage during the-to-be-reported quarter. While management projected fiscal third-quarter gross margin pressure from unfavorable foreign exchange, tariffs, freight costs and lower production tied to AI-enabled inventory optimization, the company's back-office consolidation efforts, particularly within CooperSurgical, are expected to have helped offset some of these pressures and support earnings performance. Shares of COO have lost 17.4% in the year-to-date period against the industry’s 7.3% growth. However, the S&P 500 Index has increased 12.2% in the same time frame. Image Source: Zacks Investment Research Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST. Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%. West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Medtronic plc MDT reported first-quarter fiscal 2027 adjusted earnings per share (EPS) of $1.45 per share, which rose 15.1% year over year and topped the Zacks Consensus Estimate by 4.32%. The metric excludes certain one-time adjustments, including amortization of intangible assets, restructuring and associated costs, as well as acquisition and divestiture-related items. On a GAAP basis, EPS came in at $1.14, up from 81 cents a year earlier. Revenues rose 13.7% year over year to $9.76 billion and beat the consensus mark by 3.02%. The quarter included an extra fiscal week, which benefited organic growth by approximately $570 million. Following the announcement today, MDT shares rose nearly 5% in pre-market trading. Cardiovascular revenues totaled $3.93 billion in the first quarter of fiscal 2027, up 19.5% year over year on a reported basis and 18.9% organically. Within this, Electrophysiology Therapies revenues rose 29.1%, while Interventional Cardiology Therapies revenue were up 6.5% organically. CardioVascular Surgery and Peripheral Vascular Health revenues advanced 8.1% and 11% respectively, on an organic basis. Neuroscience revenues came in at $2.68 billion, up 10.3% reported and 9.3% organically. Cranial & Spinal Technologies led the portfolio with 12.9% organic growth. Specialty Therapies revenues increased 7.4% organically, while Neuromodulation posted 3.3% organic growth. Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote Medical Surgical revenues were $2.28 billion, up 10% year over year and 10.2% organically. Surgical & Endoscopy revenues increased 9% organically, while Acute Care & Monitoring revenues rose 14.2% organically. Diabetes revenues jumped 16.9% to $843 million, with organic growth of 14.9%. U.S. revenues rose 16.1% to $4.91 billion, with organic growth of 15.8%. U.S. Cardiovascular was particularly strong, increasing 25.3%, as Electrophysiology Therapies revenues climbed 41.2%. International revenues advanced 11.4% to $4.85 billion and grew 11.6% organically. International Diabetes recorded 16.8% organic growth, while Cardiovascular increased 13.7%, highlighting strength across major overseas businesses. The gross margin in the reported quarter remained flat year over year at 65% despite a 13.8% increase in the cost of products sold, excluding amortization of intangible assets, to $3.42 billion. Research and development expenses rose 6.2% year over year to $771 million. Selling, general and administrative expenses increased 14% to $3.20 billion. The adjusted operating margin expanded 10 basis points year over year to 23.7%. Medtronic raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from the prior 6.75%-7.25% range. The company also lifted adjusted EPS guidance to $5.94-$6.00 from the prior $5.90-$6.00 outlook. The guidance incorporates an estimated neutral to 1% accretive foreign currency impact based on recent exchange rates. Medtronic also highlighted recent acquisitions of Scientia Vascular and SPR Therapeutics and continued investment in growth platforms. The Zacks Consensus Estimate projects fiscal 2027 revenues of $38.64 billion, up 6.3% from the fiscal 2026 levels, while EPS is expected to rise 7.4% to $5.94. Medtronic delivered better-than-expected earnings and revenues in the first quarter of 2027. Cardiovascular remained the key growth engine, with strong performances in Cardiac Rhythm Management and Cardiac Ablation Solutions. Neuroscience, Medical Surgical and Diabetes also delivered healthy organic growth. Management cited strong operating performance, continued innovation investments, portfolio development and commercial execution in supporting the improved 2026 outlook. During the quarter, Medtronic completed the acquisitions of Scientia Vascular and SPR Therapeutics. The company announced an expanded CE Mark indication for the Affera Mapping and Ablation System and Sphere-9 Catheter for treating ventricular arrhythmias. MDT also received FDA clearance for its next-generation Touch Surgery Aide computing platform. Medtronic stated that it has entered into a strategic partnership with Cornerstone Robotics to broaden access to robotic-assisted surgery and also announced a strategic investment in Pi-Cardia, strengthening its portfolio development efforts. Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical GMED, Envista NVST and Teleflex TFX. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an earnings yield of 6% compared to the industry’s negative 1.3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 27.9%. Envista, carrying a Zacks Rank #2 (Buy) at present, posted second-quarter 2026 adjusted earnings of 41 cents per share, exceeding the Zacks Consensus Estimate by 24.2%. Revenues of $730.5 million topped the Zacks Consensus Estimate by 2.2%. NVST has an estimated long-term earnings growth rate of 13.8% compared with the industry’s 10.8% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 19.4%. Teleflex, carrying a Zacks Rank #2 at present, posted a second-quarter 2026 adjusted EPS of $1.76, exceeding the Zacks Consensus Estimate by 37.5%. Revenues of $570.3 million outperformed the Zacks Consensus Estimate by 1.9%. TFX has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.9% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Teleflex Incorporated (TFX) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Envista Holdings Corporation (NVST) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research